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A B S T R A C T
Background: While antidepressant use during pregnancy is increasingly common, there is concern about the
possible effects of in-utero antidepressant exposure on the child. Our objective was to examine whether there is a
dose-effect of maternal serotonin reuptake inhibitors (SRI) during pregnancy on birth outcomes.
Methods: Women between 12 and 16 weeks of gestation, who were using an SRI, were eligible for participation
in this nation-wide prospective observational cohort study. Recruitment took place between April 2015 and
February 2018 (n = 145). SRI exposure and psychopathology symptoms were assessed throughout pregnancy.
Exposure was defined as SRI standardized dose at 36 weeks of gestation and mean SRI standardized dose over
total pregnancy. Multivariable linear and logistic regression were used to examine the associations with birth
weight, gestational age at birth, and being small for gestational age.
Results: Maternal SRI dose at 36 weeks of gestation was significantly associated with birth weight (adjusted
ß = -180.7, 95%CI -301.1;-60.2, p-value < 0.01) as was mean SRI standardized dose during total pregnancy
(adjusted ß = -187.3, 95%CI -322.0;-52.6, p-value < 0.01). No significant associations between maternal SRI
dose and gestational age or being small for gestational age were observed.
Limitations: Although prospective, we cannot make full causal inferences given that we did not randomize
women to different dosages.
Conclusion: These findings suggest that careful dosing of SRI use during pregnancy may prevent a negative
impact on birth weight and indicate the need for further investigation of causality.
1. Introduction
Antidepressants (ADs) are the first-choice drug treatment for mood
and anxiety disorders. The use of ADs during pregnancy has been
growing steadily (Molenaar et al., 2019), with prevalence rates ranging
between 2 and 13% (Molenaar et al., 2020). As ADs cross the placenta,
there is substantial concern about the possible effects of in utero AD
exposure on the unborn child (Ewing et al., 2015). Several studies
showed associations between in utero AD exposure and unfavorable
neonatal outcomes, such as preterm birth, low birth weight, low Apgar
score, Persistent Pulmonary Hypertension of the Neonate, and cardiac
abnormalities (Bérard et al., 2016; Corti et al., 2019; Eke et al., 2016;
Ross et al., 2013; Sujan et al., 2017). Furthermore, other studies have
shown that AD use during pregnancy has been associated with in-
creased risks of adverse developmental child outcomes, such as altered
brain development, childhood overweight and psychiatric and neuro-
behavioral outcomes (Grzeskowiak et al., 2013; Liu et al., 2017; Lugo-
Candelas et al., 2018; Skurtveit et al., 2014). Fetal programming might
account for an impact of ADs on early intra-uterine development, which
might result in both unfavorable neonatal outcomes as well as
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unfavorable long-term outcomes (Pluess and Belsky, 2011). Un-
fortunately, most of these studies are large retrospective register stu-
dies. Important confounders, especially the severity of the underlying
mood or anxiety disorder (i.e. the indication for AD treatment), are
often not controlled for. In addition, these register studies are often
based on prescription of ADs rather than actual use and information.
Finally, the dose that is actually taken is often lacking, which restricts
further understanding of a causal relationship between AD use and
child outcomes.
Given the importance of both adequate treatment of maternal
mental health as well as the life-long health of the offspring, more
clarity on the relationship between AD use during pregnancy and child
development is urgently needed (Clark, 2016). This knowledge will
support pregnant women's decision-making about whether to continue
pre-existing AD use during pregnancy, or to consider guided lowering
or discontinuation of their AD use, possibly in combination with other
non-pharmacological treatment options, such as cognitive behavioral
therapy (Bockting et al., 2018; O'Connor et al., 2019).
The current study aimed to prospectively investigate the effects of
maternal serotonin reuptake inhibitors (SRIs) daily dose on birth out-
comes. The existence of a dose-response relationship (‘biological gra-
dient’) is a strong indicator of a causal link between a specific de-
terminant and outcome although its absence should not be regarded as
precluding causation (Hill, 1965). Though SRIs have been associated
with preterm birth and suboptimal fetal growth (Eke et al., 2016;
Zhao et al., 2018), to date, findings on dose-effects of SRIs on birth
outcomes are sparse and conflicting (Oberlander et al., 2008;
Roca et al., 2011; Suri et al., 2007). We examined whether maternal SRI
daily dose is associated with birthweight, gestational age, and whether
the child is small for gestational age (SGA) in a graded way. This was
studied in a Dutch sample of pregnant women, while controlling for a
large set of confounders, including maternal depressive and anxiety
symptoms. We examined both the association between birth outcomes
and exposure to SRI dose at 36 weeks of pregnancy and the association
between birth outcomes and mean dose exposure during total preg-
nancy.
2. Methods
2.1. Study design and participants
The present study was an observational cohort study of pregnant
women with SRI use during pregnancy. It was part of a larger nation-
wide research project on antidepressant use during pregnancy, in-
cluding both a randomized controlled trial (RCT), called ‘Stop or Go’
(NTR4694), in which women were randomized to continue or dis-
continue SRIs during pregnancy (Molenaar et al., 2016), and a pro-
spective observational cohort. This study was approved by the Medical
Ethical Committee of the Erasmus Medical Center (MEC-2014–505).
The current study reports on participants from the observational cohort
only.
Women were recruited between April 2015 and February 2018
during their prenatal booking visit in midwifery practices and hospitals,
through general practitioners, or through advertisement in (social)
media. Women received study information on both the RCT and the
observational cohort. When women were not eligible or declined to
participate in the RCT, they were asked to participate in the observa-
tional cohort. Written informed consent was necessary for participation.
For the present observational study, participants were considered
eligible if they were between 12 and 16 weeks pregnant, used an SRI
(either a Selective Serotonin Reuptake Inhibitor (SSRI) or Serotonin
Noradrenalin Reuptake Inhibitor (SNRI)) in their first trimester, and
were proficient in Dutch and/or English. Women with a multiple
pregnancy were non-eligible.
2.2. SRI dose
SRI type and current daily dose were assessed at baseline (between
12 and 16 weeks of gestation) and at 24 and 36 weeks of gestation. To
ensure correct dosing information, medication adherence was assessed,
using the medication adherence rating scale (Horne and
Weinman, 1999). We standardized the prescribed dose per individual
by computing dose equivalent scores, as not all SRI types are equally
dosed to reach their therapeutic effect. Dose equivalent scores were
computed by dividing the prescribed dose by the standard initial dose
for the SRI type prescribed. Standard initial doses according to the
American pharmaceutical treatment guidelines (the National Library of
Medicine of the National Institutes of Health (https://www.nlm.nih.
gov)) are: citalopram 20 mg, escitalopram 10 mg, fluoxetine 20 mg,
fluvoxamine 100 mg, paroxetine 20 mg, sertraline 50 mg, and venla-
faxine 75 mg.
2.3. Birth outcomes
Outcomes were: birth weight (in grams), gestational age at birth (in
days), and small for gestational age (SGA). Birth weight was reported
by the mothers. In the Netherlands, all mothers receive a medical
document stating the birth weight. Gestational age was calculated from
the reported due date at baseline, as determined by ultrasound between
8 and 12 weeks of gestation, and the actual date of birth. Infants were
classified as SGA when their birth weight was below the tenth per-
centile for the corresponding gestational age and gender according to
the Hoftiezer standards (Hoftiezer et al., 2019). These standards are
based on live-born singleton infants born in The Netherlands between
2000 and 2014.
2.4. Confounding factors
Potential confounding factors were selected based on literature and
included variables that have shown associations with SRI dose and
predictive of birth outcomes and were unlikely to be part of the causal
chain from SRI exposure to outcome. Maternal age and parity (primi-
parous/multiparous) were assessed at baseline (Campbell et al., 2012).
Socio-economic status was defined by highest level of education (pri-
mary/secondary education or higher education) and whether partici-
pants had a paid job (y/n) at baseline (Amini et al., 2018; Von Soest
et al., 2012). To enable control for symptoms of depression and anxiety
during pregnancy in the analysis (Ding et al., 2014; Grote et al., 2010),
the Edinburgh Postnatal Depression Scale (EPDS) (Bergink et al., 2011),
and the short-form of the state scale of the State-Trait Anxiety Inventory
(STAI) (Marteau and Bekker, 1992) were administered at baseline and
24 and 36 weeks of gestation. EPDS scores range between 0 and 30,
with a score of 11 or higher indicating a high risk of depressive disorder
(Bergink et al., 2011). STAI scores range between 20 and 80, with
higher scores indicating greater anxiety. Mean sum scores over the
three measurements were calculated to represent symptomatology
during total pregnancy. In addition, we accounted for current and
lifetime diagnosis of depression and anxiety as measured with the
Structured Clinical Interview for DSM-IV-TR Axis I disorders (SCID-I) at
baseline (First et al., 2002).
2.4.1. Multiple imputation of missing data
To avoid potential selection bias and a decrease in statistical power
associated with complete case analysis, missing values for all outcomes
were imputed (White et al., 2011). The percentage of missing data in
the present study ranged from 9.0% to 22.8% (mean 15.3%). For 97
participants (66.7%) at least one variable was missing. Birth weight was
missing in 14.5% and gestational age in 13.8%. Missing data were
imputed using multiple imputation by chained equations under the
assumption that missing values were missing at random (MAR) or
missing completely at random (MCAR). All missing variables, including
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the outcome variables, were imputed (Sterne et al., 2009). Multiple
data sets (N = 10) were generated to account for the uncertainty in
imputed data. We report on the pooled estimates. To test the robustness
of our findings, we performed sensitivity analyses using the non-im-
puted data set.
2.5. Statistical analyses
First, descriptive statistics of the study population were provided.
We then used univariable linear and logistic regression to examine the
associations of dose-equivalent score at 36 weeks of gestation and mean
dose-equivalent score over total pregnancy as continuous variables with
continuous birth outcomes (birth weight, gestational age) and the di-
chotomous variable SGA, respectively. Subsequently, we repeated the
analyses, in which we adjusted for confounding factors, following a
two-step procedure. In the partially adjusted model we included con-
founding factors with a solid evidence-based foundation (maternal age,
parity, mean EPDS and STAI scores) (Campbell et al., 2012; Ding et al.,
2014; Grote et al., 2010). In the fully adjusted model we additionally
corrected for education level, having a paid job and a current or lifetime
SCID diagnosis of depression and anxiety (Amini et al., 2018; Pluess and
Belsky, 2011; Von Soest et al., 2012). Lastly, we performed a sensitivity
analysis only including participants with SSRIs and excluding those
with SNRIs. The Statistical Package for Social Sciences (SPSS) version
25.0 was used for data analyses and the significance level was set at
0.05, two sided.
3. Results
A total of 478 women were referred for counselling and consecutive
screening for eligibility. This resulted in a final study sample for the
current observational study of 145 women (Fig. 1). Maternal and neo-
natal characteristics of the sample before multiple imputation are listed
in Table 1. Besides a diagnosis (past or present) of depression or anxiety
(including panic disorder (n = 38), agoraphobia (n = 34), social
phobia (n = 21), specific phobia (n = 19), obsessive-compulsive dis-
order (n = 22), post-traumatic stress disorder (n = 17), generalized
anxiety disorder (n = 4), and anxiety not otherwise specified (n = 7)),
we found the following diagnoses (past or present) in our study cohort:
alcohol misuse/dependency (n = 6), substance misuse/dependency
(n = 4), psychotic disorder (n = 4), anorexia (n = 11), bulimia
(n = 6), binge eating disorder (n = 2), somatization disorder (n = 1),
and pain disorder (n = 3). Mean EPDS scores throughout pregnancy
remained stable and below the cut-off score of 11 (Bergink et al., 2011).
At baseline, 17.4% of women scored above the EPDS cut-off score, and
18.5% and 15.2% scored above the cut-off score at 24 and 36 weeks of
gestation respectively.
3.1. Effects of maternal SRI dose at 36 weeks of gestation on birth weight,
gestational age, and SGA
The analysis of maternal SRI dose at 36 weeks of gestation showed a
negative association with birth weight (β = −156.7, 95%CI
−280.0;−33.4, df=1, p-value = 0.01), which remained present after
adjustment for the full set of confounders (adjusted β = −180.7,
95%CI −301.1;−60.2, df=9, p-value < 0.01). No significant asso-
ciations of SRI dose at 36 weeks of gestation with gestational age
(β = −1.3, 95%CI −3.7;1.1, df=1, p-value = 0.28) or SGA
(OR = 1.2, 95%CI 0.7;2.1, df=1, p-value = 0.55) were observed
(Table 2). Sensitivity analyses both with the non-imputed dataset and
with exclusion of participants using SNRIs showed similar results.
Fig. 1. Flow diagram of participant inclusion.
Table 1
Maternal and neonatal characteristics (before multiple imputation).
Maternal demographic characteristics N = 145a
Mean SD
Age at enrolment in years 32.2 4.7
N %
Primiparous, yes 76 57.6
Level of education, high 77 60.6
Paid job, yes 105 79.5



















Duration of SRI use in months, median (range)b 48 (1 – 252)
Mean dose equivalence during pregnancy 1.2 0.7
Dose equivalence at 36 weeks of pregnancy 1.1 0.8
Mean EPDS score during pregnancyc 6.9 4.0
Mean STAI score during pregnancyd 35.9 9.3
N %
SCID diagnosis of depressione 101 70.1
SCID diagnosis of anxietyf 95 66.0
Neonatal characteristics
Mean SD
Birth weight in grams 3347.1 509.2
Gestational age at birth in days 275.1 10.3
N %
Small for gestational age (SGA, < 10th percentile) 18 14.5
a Numbers may not always sum up due to missing data.
b Values for this variable were nonnormally distributed, and therefore,
median and range are reported.
c Mean EPDS score calculated from sum scores at 16, 24 and 36 weeks of
pregnancy.
d Mean STAI score calculated from sum scores at 16, 24 and 36 weeks of
pregnancy.
e Lifetime (previous or current) SCID diagnosis of depression.
f Lifetime (previous or current) SCID diagnosis of anxiety disorder.
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3.2. Effects of mean maternal SRI dose on birth weight, gestational age, and
SGA
Similar results were observed for the effects of mean SRI dose
during total pregnancy on birth outcomes. An association was found
between mean SRI dose and birth weight (β = −166.3, 95%CI
−299.3;−33.2, df=1, p-value = 0.01), which remained present after
adjustment for the full set of confounding factors (adjusted
β = −187.3, 95%CI −322.0;−52.6, df=9, p-value < 0.01). However,
no significant associations were found between mean SRI dose and
gestational age (β = −1.8, 95%CI −4.5;0.9, df=1, p-value = 0.18) or
between mean SRI dose and SGA (OR = 1.2, 95%CI 0.6;2.3, df=1, p-
value = 0.59). Sensitivity analyses with the non-imputed dataset
showed similar results.
4. Discussion
In this prospective observational cohort study, we found that, while
controlling for maternal depressive and anxiety symptoms, maternal
SRI dose during pregnancy, both assessed at 36 weeks of gestation and
averaged over total pregnancy, was significantly associated with birth
weight of the offspring. Higher daily dose equivalent of maternal SRI
during pregnancy was associated with lower birth weight (a 180–190 g
birthweight reduction per single dose equivalent increase). Maternal
SRI dose at 36 weeks of gestation and mean SRI dose during total
pregnancy were not significantly associated with gestational age of the
offspring or with being small for gestational age.
Previously, the association between antidepressant use and birth
outcomes has mostly been investigated in population-based registers.
They often provide large sample sizes and sufficient information on
prescribed medication. However, controlling for confounders, espe-
cially regarding severity of maternal depressive and anxiety symptoms,
can prove to be difficult. Choosing a suitable control population is not
straightforward. The effect estimates of children with maternal AD
exposure can be compared to those of children born to asymptomatic
and unexposed women. Unfortunately, these groups are likely to differ
in measurable and unmeasurable factors, more than the groups in our
study with varying doses. Examples of these factors include genetics,
underlying disease severity and symptomatology, possibly leading to an
overestimation of the consequences of AD exposure. A different strategy
is therefore to compare children with exposure to maternal ADs with
children born to depressed (symptomatic) women without AD exposure
(Mitchell and Goodman, 2018). However, many women on ADs will be
in remission and will not have symptoms of depression or anxiety
during pregnancy, and are thus not comparable to symptomatic
women. Such a comparison can result in an underestimation of the
consequences of AD exposure, as symptoms of depression and anxiety
during pregnancy have also been associated with negative child out-
comes, including lower birth weight (Ding et al., 2014; Grote et al.,
2010). A recent study in Norway summarized the conflicting study
results and attempted to overcome methodologic issues by employing a
sibling design, minimizing putative confounding factors related to
maternal factors (Nezvalová-Henriksen et al., 2016). They found that
SSRI exposure during two or more trimesters was associated with a
decrease in birthweight of 205 g.
In the current study, we focused on gaining more insight into
causality by evaluating dose-effect within a group of women using
antidepressants, while controlling for maternal depressive and anxiety
symptoms. Dose-effect or biological gradient is one of the nine Bradford
Hill criteria of causality, and although the presence of a dose-effect
relationship does not prove causation, it strengthens earlier findings in
that direction (Hill, 1965). We observed a dose-effect of maternal SRI
use on birth weight, but did not find a significant association between
maternal SRI dose and gestational age at birth. These findings are in
contrast to earlier dose-effect studies (Oberlander et al., 2008;
Roca et al., 2011; Suri et al., 2007). An important difference between
our study and two of these previous studies is that they solely included
women with a history of major depressive disorder (Roca et al., 2011;
Suri et al., 2007), while the current study included women independent
of their psychiatric history, correcting for this during analyses. The
third previous study was a registry study, facing difficulties with cor-
recting for measures not routinely registered (Oberlander et al., 2008).
Another potential explanation is the difference in used SRI exposure.
Where the previous studies examined the impact of a high versus low
dose, we used a continuous dose measurement, standardizing the dif-
ferent SRI types for initial dosage. Important to note is that the absence
of a dose-effect in our study does not translate to an absence of an
association between in utero SRI exposure and decreased gestational
age at birth, as we did not include a control group without SRI use.
The pathophysiological mechanism underlying the association be-
tween prenatal SRI exposure and birth weight remains uncertain, al-
though several pathways have been suggested. Firstly, it has been
suggested that high levels of serotonin are associated with lower growth
hormone levels in the pituitary gland (Castrogiovanni et al., 2014),
which can negatively impact the growth of the fetus both directly and
by decreasing the production of insulin-like growth factor, which in
turn regulates body weight (Nawathe et al., 2016). Another proposed
mechanism is through programming of the fetal hypothalamic-pitui-
tary-adrenal (HPA) axis. An animal study showed that in utero exposure
to an SRI increased fetal levels of cortisol and adrenocorticotrophic
hormone (Morrison et al., 2004), which can influence fetal develop-
ment as well as growth hormone and insulin-like growth factor activity
(Agha and Monson, 2007). Lastly, SRIs might impact placental function
directly. Disrupted placental serotonin synthetic pathways and pla-
cental serotonin levels have been associated with fetal growth restric-
tions (Kliman et al., 2018; Ranzil et al., 2019). Moreover, serotonin acts
as a vasoconstrictor (Cruz et al., 1997), potentially influencing fetal
growth when present to a greater extent due to maternal SRI use.
Jointly, these observations, in combination with our observed dose-ef-
fect, make an influence of maternal SRI on fetal growth plausible.
Table 2
Dose effect of SRI medication on birth outcomes.




95% CI p-value Partially adjusteda
(ß / OR)
95% CI p-value Fully adjustedb (ß
/ OR)
95%CI p-value
Birth weight (grams) −156.7 −280.0;−33.4 0.01 −158.2 −280.2;−36.2 0.01 −180.7 −301.1;−60.2 <0.01
Gestational age (days) −1.3 −3.7;1.1 0.28 −1.3 −3.6;1.0 0.26 −1.5 −3.8;0.9 0.23
SGA (<10th percentile) 1.2 0.7;2.1 0.55 1.2 0.7;2.1 0.54 1.3 0.7;2.4 0.37
Effects of mean dose over total pregnancy
Birth weight (grams) −166.3 −299.3;−33.2 0.01 −165.5 −299.5;−31.6 0.02 −187.3 −322.0;−52.6 <0.01
Gestational age (days) −1.8 −4.5;0.9 0.18 −1.7 −4.3;0.9 0.20 −1.9 −4.5;0.8 0.18
SGA (<10th percentile) 1.2 0.6;2.3 0.59 1.2 0.6;2.3 0.60 1.3 0.7;2.5 0.47
a Adjusted for maternal age, parity, mean EPDS score, mean STAI score.
b Adjusted for maternal age, parity, mean EPDS score, mean STAI score, education level, paid job, SCID diagnosis of depression and SCID diagnosis of anxiety.
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4.1. Strengths and limitations
A major strength of this study is the prospective design in which we
used longitudinal data for both the measurement of SRI exposure and
maternal symptomatology and current and past psychiatric diagnoses.
SRI dose was assessed throughout pregnancy and postpartum, allowing
us to calculate a mean dose during pregnancy, to account for women
fluctuating in their daily dosage. Maternal symptomatology during
pregnancy, as measured with the EPDS and STAI, was also questioned
during each study assessment, allowing us to correct for mean symp-
tomatology during pregnancy instead of using a single snapshot.
Furthermore, we used the standardized SCID-I interview at baseline to
determine psychiatric history, which allows for a more reliable classi-
fication compared to register-based studies that mostly rely on un-
standardized hospital data. Lastly, we included women with SRI use
independent of their psychiatric history, which is important for the
generalizability, since SRIs are not only prescribed for major depressive
disorder. A recent study in Canada investigated treatment indications
for ADs in primary care between 2006 and 2015 and found that only
55.2% of these prescriptions were made for major depressive disorder
(Wong et al., 2016).
However, our study also has its limitations. Although prospective,
we cannot make full causal inferences given that we did not randomize
women to different dosages. We corrected for a range of important
confounders, including current and lifetime diagnosis of depression
and/or anxiety. Other psychiatric diagnoses and other psychotropic
medication use during pregnancy were assessed, but due to their lim-
ited and variable presence within our population, they were not con-
trolled for. In addition, we used standard initial doses according to the
American pharmaceutical treatment guidelines to calculate dose
equivalent scores. We did not take into account drug potency, in-
dividual metabolization rate, which may be highly variable during
pregnancy by factors such as genotype (Avram et al., 2016), and pla-
cental transfer per SRI type, which can vary slightly (Frazer, 2001;
Rampono et al., 2009). Analysis of SRI serum levels would have been an
interesting addition to the current study. Although a dose-effect re-
lationship is an indicator for causality, a more detailed investigation of
the biological mechanisms, including placental transfer, is needed to
make more definitive conclusions on causality. Out of the 478 women
referred for counselling, 248 women declined to participate, without
providing a reason or background information, conforming to common
and local ethical procedures. These women might have differed in their
psychiatric history, current symptomatology and treatment manage-
ment, possibly limiting the generalizability of our results. However, it
seems unlikely in our view that the association between SRI dose and
birth weight would materially differ between those women who parti-
cipated and who did not. Lastly, the non-significant findings on gesta-
tional age and SGA could be the result of the small sample size.
5. Conclusion
The inverse dose-effect between SRI use during pregnancy and birth
weight that was found in this study indicates that management options
regarding SRI use during pregnancy should not be limited to continuing
or discontinuing. Instead, these findings suggest that careful dosing of
serotonin reuptake inhibitor use during pregnancy needs to be con-
sidered on an individual level, as this may prevent a negative impact on
birth weight. The necessity of SRI use needs to be evaluated, preferably
before pregnancy, and other treatment options such as psychological
interventions, if available, need to be actively considered. It may be
that adding additional psychological interventions may result in a de-
creased dose needed to be effective (Bockting et al., 2015). Future re-
search should focus on relating birth weight to blood serum levels of
SRIs, serum level of SRIs in umbilical cord or meconium, and the re-
plication of our findings in large samples while accounting for relevant
confounding factors. Finally, a randomized controlled trial could more
definitively establish a causal relationship.
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